Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence - Wikidata - wikimedia - TriplyDB

Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence

Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence

http://www.wikidata.org/entity/Q28277232

about

The emerging role of histone lysine demethylases in prostate cancer G9a and Glp methylate lysine 373 in the tumor suppressor p53 Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation LSD1/CoREST is an allosteric nanoscale clamp regulated by H3-histone-tail molecular recognition.Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting The role of histone demethylases in cancer therapy Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention Histone methylation restrains the expression of subtype-specific genes during terminal neuronal differentiation in Caenorhabditis elegans Formaldehyde in brain: an overlooked player in neurodegeneration?Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation Epigenetic modulators as therapeutic targets in prostate cancer Epigenome-based personalized medicine in human cancer KDM1 class flavin-dependent protein lysine demethylases Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology LSD1 inhibition: a therapeutic strategy in cancer?Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2 Catalytic mechanism investigation of lysine-specific demethylase 1 (LSD1): a computational study LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16 The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer Protein-Protein Interactions Mediated by Helical Tertiary Structure Motifs.Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.Sex differences in histone modifications in the neonatal mouse brain Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.Prostate cancer-associated gene expression alterations determined from needle biopsies.Vitamin D and the epigenome.Cancer epigenetics: a brief review.Epigenetics: an emerging player in gastric cancer Exploiting Epigenetic Alterations in Prostate Cancer.Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice.Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)PKCα-mediated phosphorylation of LSD1 is required for presynaptic plasticity and hippocampal learning and memory Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1 Chromatin proteins and modifications as drug targets.Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes.

P2860

Q21245762-87250238-74DB-4184-A854-B65CB6982115 Q24298004-65951139-8B9B-43D4-8D80-977BA619B8CA Q24302392-36515616-CE4E-40AD-B351-B881A4978C41 Q24623687-7D5DB621-6458-42A5-A0B5-C0DB76268680 Q24651323-9DA81011-A340-4F97-8855-14C73DDBA084 Q26744441-1D1880B2-6113-4590-9789-96A9CB95EFE7 Q26745452-8A01C2DE-E058-4EB4-82A7-4AFFA6E59F10 Q26768602-D8033910-69B4-46F3-B595-183FBEC13C77 Q26864687-1DFE5A15-7646-488F-8E22-A93CD6F33EFF Q26994739-C8CB064C-9EAE-4F18-B797-6E058C1D3FCC Q27318351-8CDD1207-AE76-4B3D-80DD-D86265975BFC Q27691458-28EFF532-D83C-4DC8-B1B4-B7004D0BBA11 Q27703586-1390A14B-6D70-4DCE-91C0-BA6455AAC543 Q28071912-7B99624D-D450-4B1E-8351-923B77F01E35 Q28083951-072803BF-9A24-4CFB-AD59-F329DAE04769 Q28084876-AE8C6295-7DB6-4D3C-A720-2E7577DE21AD Q28269080-ACC36A19-2B34-4861-9D7C-9A07C3A337DA Q28274561-2C0ACE9E-845B-4A76-BF3C-55B6F3AF465E Q28280935-AB75F6B6-C78D-4125-B925-D095381779D9 Q28477309-0BCFF2AD-2972-4FA8-B5AB-D073BD1641E0 Q28593421-9F61E8F4-4432-4C1A-B2DC-7B33CD922BD8 Q28687241-D8426873-5FD5-4032-84C5-13B562884E1B Q30378305-14D04958-FC2E-47D6-A64C-FDCDF69E5B74 Q30414643-E2E0FBCF-7E03-428F-8B78-9FC1A9E7F170 Q30439867-EC2BE6AE-DB54-4CFD-B88F-59873D33DE29 Q33314914-C0FF54FB-2D0D-464E-BB35-6B6527D454BA Q33430210-BAAAC989-C34A-40A8-A6A2-38C8B8318E83 Q33569349-F7ADE61A-7A2D-448D-9C1E-74C198D041B2 Q33614190-82A551F7-2563-43FB-892F-FE50E1050375 Q33718259-9999BCDB-D33E-4323-BD0D-7FDB4D7F7E0C Q33755160-ACF95367-50BD-4E5B-AFA6-346C44DF478A Q33771160-ECD6FCDA-B53E-418F-B971-1BCAD757E7DA Q33779673-A70D1064-FCDE-438E-B8FA-5EF419B628FB Q33815903-7837B77E-8456-4CD6-B2F7-F195EBDBEFFF Q33838513-B20D503C-BC02-45CD-831F-DCC5BB1A4D72 Q33885079-B8964F7D-EAB8-4825-A29A-DCFBDD74D714 Q33952953-9A8E92E8-47F0-4858-8E7E-8705893BE634 Q33954219-4DD24BD4-C107-40AD-A1A2-85289AEADA49 Q34038652-19D9FC97-248B-4A39-A677-27C72DA41B0A Q34084746-7C2A2C6F-027F-4402-BC7D-EF71D6D11F1F

P2860

Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence

http://www.wikidata.org/entity/Q28277232

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Androgen receptor coactivators ...... of prostate cancer recurrence

@ast

Androgen receptor coactivators ...... of prostate cancer recurrence

@en

Androgen receptor coactivators ...... of prostate cancer recurrence

@nl

type

label

Androgen receptor coactivators ...... of prostate cancer recurrence

@ast

Androgen receptor coactivators ...... of prostate cancer recurrence

@en

Androgen receptor coactivators ...... of prostate cancer recurrence

@nl

prefLabel

Androgen receptor coactivators ...... of prostate cancer recurrence

@ast

Androgen receptor coactivators ...... of prostate cancer recurrence

@en

Androgen receptor coactivators ...... of prostate cancer recurrence

@nl

P1433

Q28277232-0BF01FD2-DEC5-4019-AEB9-CF7A6B903E28

P1476

Q28277232-064E18C5-3E75-4E36-92F7-FE9B34D45533

P2093

Q28277232-3C2DE48B-621E-4E56-A179-17F3591F2912

Q28277232-49FB2632-2701-4D47-AEFB-C5C18689A536

Q28277232-575BFFC0-1F0E-4869-B912-806D081EC3EB

Q28277232-5EA5B3EC-EF64-4ED3-958E-283A47E659D3

Q28277232-67B9C23C-1831-41C6-AD82-2B8E9B798287

Q28277232-710D9E85-ADA8-4B30-AB10-F75202B0795E

Q28277232-789F7A8D-7787-4F2D-BC0A-86CDDBF376FC

Q28277232-94222D15-961B-4565-8269-2A9015628FC3

Q28277232-94D0C3C5-0469-4116-98DD-41895E30D79B

Q28277232-CAE750BF-3D18-4EE6-B083-B9B30652816E

P304

Q28277232-ABFD32A0-2C1D-4ED2-B943-A81A6B6DC00E

P31

Q28277232-CC9FF915-129E-43B9-B6D7-414B51D7C8A9

P3181

Q28277232-2FBE1988-0B48-4712-ACE3-E109D5F2849D

P356

Q28277232-5217E240-5315-4FEB-92BE-4E89C5EF3768

P407

Q28277232-896E615D-CA9A-4F42-AE99-A3384C8D52EA

P433

Q28277232-87679773-7F94-41FE-AF2E-B4756EA79A2C

P478

Q28277232-3133DC55-40D8-4CBC-889D-4883DBEF706D

P50

Q28277232-478A576B-C6CE-4738-9A20-7E577F3B8E6B

Q28277232-7A098C7B-DFC0-49A4-9BAF-574D3E2DC193

P577

Q28277232-F203E6FD-D2F8-42F8-B915-F52EB9E6A256

P698

Q28277232-9E7571E3-C1B6-4C2E-BDC4-A82A19EF2B23

P3181

P356

0008-5472.CAN-06-1570

P1433

Cancer Research

P1476

Androgen receptor coactivators ...... of prostate cancer recurrence

@en

P2093

Eric Metzger

http://www.w3.org/2001/XMLSchema#string

Gerold Solleder

http://www.w3.org/2001/XMLSchema#string

Jörg Ellinger

http://www.w3.org/2001/XMLSchema#string

Lucia Gullotti

http://www.w3.org/2001/XMLSchema#string

Nicolaus Friedrichs

http://www.w3.org/2001/XMLSchema#string

Patrick J Bastian

http://www.w3.org/2001/XMLSchema#string

Philip Kahl

http://www.w3.org/2001/XMLSchema#string

Reinhard Buettner

http://www.w3.org/2001/XMLSchema#string

Roland Schüle

http://www.w3.org/2001/XMLSchema#string

Roland Vorreuther

http://www.w3.org/2001/XMLSchema#string

P304

11341-11347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

686594

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-06-1570

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Lukas C Heukamp

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17145880

http://www.w3.org/2001/XMLSchema#string